Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Artifacts Summary
.... 14.1 Adaptation
.... 14.2 BaselineMeasureEvidence
.... 14.3 BaselineMeasureReport
.... 14.4 BookCitation
.... 14.5 BookPartCitation
.... 14.6 CertaintyOfEvidence
.... 14.7 Classification
.... 14.8 CohortDefinition
.... 14.9 Comment
.... 14.10 ComparativeBaselineMeasureEvidence
.... 14.11 ComparativeEvidence
.... 14.12 ComparativeEvidenceReport
.... 14.13 ComparativeEvidenceReportSubject
.... 14.14 ComparativeEvidenceSynthesisReport
.... 14.15 ComparativeParticipantFlowEvidence
.... 14.16 ComparatorDefinition
.... 14.17 ComparatorGroup
.... 14.18 ComparatorOnlyEvidence
.... 14.19 Comparison
.... 14.20 CompositeRating
.... 14.21 ConceptualCohortDefinition
.... 14.22 DatabaseCitation
.... 14.23 DatabaseEntryCitation
.... 14.24 DataDictionaryCodeSystem
.... 14.25 DatasetCitation
.... 14.26 DateAsRating
.... 14.27 DichotomousPatientImportantOutcome
.... 14.28 EndpointAnalysisPlan
.... 14.29 EvidenceList
.... 14.30 EvidenceMap
.... 14.31 EvidenceMeasureReportPackage
.... 14.32 EvidenceReport
.... 14.33 EvidenceReportPackage
.... 14.34 EvidenceReportSubject
.... 14.35 EvidenceSynthesisEvidence
.... 14.36 EvidenceTableReportPackage
.... 14.37 ExposureDefinition
.... 14.38 ExposureGroup
.... 14.39 GroupAssignment
.... 14.40 GroupR6
.... 14.41 Guideline
.... 14.42 InterventionOnlyEvidence
.... 14.43 JournalArticleCitation
.... 14.44 M11Report
.... 14.45 M11ResearchStudy
.... 14.46 MetaanalysisEligibilityCriteria
.... 14.47 MetaanalysisOutcomeDefinition
.... 14.48 MetaanalysisStudyGroup
.... 14.49 NetEffectContribution
.... 14.50 NetEffectContributionList
.... 14.51 NetEffectContributions
.... 14.52 NetEffectEstimate
.... 14.53 NonComparativeEvidence
.... 14.54 OutcomeDefinition
.... 14.55 OutcomeImportance
.... 14.56 OutcomeList
.... 14.57 OutcomeMeasureReport
.... 14.58 OutcomeMeasureSynthesisReport
.... 14.59 ParticipantFlowEvidence
.... 14.60 ParticipantFlowEvidenceVariable
.... 14.61 ParticipantFlowReport
.... 14.62 PreprintCitation
.... 14.63 Rating
.... 14.64 Recommendation
.... 14.65 RecommendationAction
.... 14.66 RecommendationEligibilityCriteria
.... 14.67 RecommendationJustification
.... 14.68 RecommendationPlan
.... 14.69 ResearchStudyDataDictionary
.... 14.70 RiskOfBias
.... 14.71 SearchResults
.... 14.72 SearchStrategy
.... 14.73 SingleStudyEvidence
.... 14.74 SoaPlanDefinition
.... 14.75 SoftwareCitation
.... 14.76 StatisticModel
.... 14.77 StudyEligibilityCriteria
.... 14.78 StudyGroup
.... 14.79 SummaryOfFindings
.... 14.80 SummaryOfNetEffect
.... 14.81 SystematicReview
.... 14.82 SystematicReviewEligibilityCriteria
.... 14.83 SystematicReviewExcludedStudies
.... 14.84 SystematicReviewIncludedStudies
.... 14.85 VariableDefinition
.... 14.86 WebPageCitation
.... 14.87 ArtifactApprovalDate
.... 14.88 ArtifactAssessmentCompared
.... 14.89 ArtifactAssessmentDateAsRating
.... 14.90 ArtifactEffectivePeriod
.... 14.91 ArtifactLastReviewDate
.... 14.92 CharacteristicTiming
.... 14.93 EvidenceVariableClassifier
.... 14.94 EvidenceVariableConditional
.... 14.95 EvidenceVariableConstraint
.... 14.96 EvidenceVariableDataCleaning
.... 14.97 EvidenceVariableDataStorage
.... 14.98 EvidenceVariableMissingData
.... 14.99 EvidenceVariablePeriod
.... 14.100 ResearchStudyEstimand
.... 14.101 ResearchStudyExcludedStudy
.... 14.102 ResearchStudyIncludedStudy
.... 14.103 ResearchStudyNumberOfStudiesIdentified
.... 14.104 ResearchStudyNumberOfStudiesIncluded
.... 14.105 ResearchStudyResultAsComposition
.... 14.106 ResearchStudySaeReportingMethod
.... 14.107 ResearchStudySearchStrategy
.... 14.108 ResearchStudySponsorConfidentialityStatement
.... 14.109 ResearchStudyStudyAmendment
.... 14.110 ResearchStudySystematicReviewEligibilityCriteria
.... 14.111 StatisticModelExpression
.... 14.112 StatisticModelIncludeIf
.... 14.113 Evidence Report Contributor Role Value Set
.... 14.114 Evidence Variable Role Subtype Value Set
.... 14.115 Recommendation Justification Classifier Codes Value Set
.... 14.116 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 14.117 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.118 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 14.119 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 14.120 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 14.121 179899
.... 14.122 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 14.123 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 14.124 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 14.125 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 14.126 19967827 Wonder woman was Argentine and her real name was Evita.
.... 14.127 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 14.128 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 14.129 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 14.130 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 14.131 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 14.132 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 14.133 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 14.134 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 14.135 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 14.136 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 14.137 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 14.138 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 14.139 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 14.140 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 14.141 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 14.142 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 14.143 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 14.144 27979893 (6). Glycemic Targets.
.... 14.145 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 14.146 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 14.147 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 14.148 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 14.149 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 14.150 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 14.151 30467172 Finding my inner Wonder Woman.
.... 14.152 34871555 What Can Wonder Woman Teach Radiologists?
.... 14.153 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 14.154 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 14.155 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 14.156 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 14.157 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 14.158 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.159 Adults with type 2 diabetes
.... 14.160 Adults with type 2 diabetes and CVD and CKD
.... 14.161 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 14.162 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.163 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 14.164 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 14.165 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 14.166 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 14.167 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 14.168 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.169 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.170 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 14.171 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.172 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.173 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.174 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.175 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 14.176 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.177 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 14.178 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.179 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.180 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 14.181 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 14.182 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 14.183 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 14.184 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 14.185 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 14.186 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 14.187 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 14.188 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 14.189 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 14.190 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 14.191 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 14.192 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 14.193 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 14.194 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 14.195 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 14.196 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 14.197 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 14.198 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 14.199 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 14.200 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 14.201 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 14.202 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.203 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.204 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.205 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 14.206 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.207 ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.208 ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 14.209 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.210 ComparatorGroup: Obese patients ≥ 18 years old without bariatric surgery
.... 14.211 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.212 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 14.213 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 14.214 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.215 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.216 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.217 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.218 Composite Rating of FOI 153881 for Project FOI 112280
.... 14.219 Computable_Publishing_LLC
.... 14.220 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 14.221 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.222 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.223 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.224 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.225 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 14.226 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 14.227 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 14.228 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 14.229 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 14.230 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 14.231 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 14.232 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 14.233 ConceptualCohortDefinition: Nonfatal stroke
.... 14.234 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter
.... 14.235 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter with Ranges
.... 14.236 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 14.237 ConceptualCohortDefinition: Severe obesity
.... 14.238 ConceptualCohortDefinition: T1DM or T2DM
.... 14.239 ConceptualCohortDefinition: T1DM-specific criteria
.... 14.240 ConceptualCohortDefinition: T2DM-specific criteria
.... 14.241 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 14.242 ConceptualCohortDefinition_Cardiovascular_event
.... 14.243 COVID_19PneumoniaHospitalizedAdult
.... 14.244 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.245 DatabaseCitation: Citation for FEvIR Platform
.... 14.246 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.247 DataDictionary: Measuring the Rate of Scientific Knowledge Transfer
.... 14.248 DataDictionary: phs003190
.... 14.249 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 14.250 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 14.251 Delany-Moretlwe 2022 clinical trial
.... 14.252 Diabetes treatment medication
.... 14.253 EBMImplementationGuideProfile Value Set
.... 14.254 Eligibility criteria for NMA_Diabetes
.... 14.255 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 14.256 EvidenceList: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 14.257 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.258 EvidenceMap: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.259 EvidenceReportSectionCode Value Set
.... 14.260 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.261 EvidenceVariableRoleSubtype Value Set
.... 14.262 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.263 ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.264 ExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 14.265 ExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 14.266 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 14.267 ExposureVariable: Age (as continuous variable)
.... 14.268 ExposureVariable: Body Mass Index (as continuous variable)
.... 14.269 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 14.270 ExposureVariable: pht013093.v1.p1 RACE
.... 14.271 ExposureVariable: pht013093.v1.p1 SEX
.... 14.272 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 14.273 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 14.274 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 14.275 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 14.276 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 14.277 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 14.278 ExposureVariable: pht013094.v1.p1 Source_Type
.... 14.279 GLP-1 RA Group in Adults with type 2 diabetes
.... 14.280 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 14.281 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.282 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.283 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 14.284 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 14.285 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 14.286 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 14.287 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 14.288 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 14.289 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.290 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 14.291 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.292 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.293 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.294 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.295 Investigator
.... 14.296 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 14.297 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 14.298 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.299 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.300 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.301 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.302 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.303 M11 IGBJ Protocol Example Eligibility Criteria
.... 14.304 M11 IGBJ Protocol Example for EBMonFHIR IG
.... 14.305 M11 Report Template Instructions
.... 14.306 MAGIC-derived Evidence: All-cause mortality Comparator Evidence
.... 14.307 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.308 MAGIC-derived Evidence: Body weight Comparator Evidence
.... 14.309 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.310 MAGIC-derived Evidence: Cardiovascular mortality Comparator Evidence
.... 14.311 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.312 MAGIC-derived Evidence: Diabetic ketoacidosis Comparator Evidence
.... 14.313 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.314 MAGIC-derived Evidence: End-stage kidney disease Comparator Evidence
.... 14.315 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.316 MAGIC-derived Evidence: Genital infection Comparator Evidence
.... 14.317 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.318 MAGIC-derived Evidence: Health-related quality of life Comparator Evidence
.... 14.319 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.320 MAGIC-derived Evidence: Heart failure Comparator Evidence
.... 14.321 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.322 MAGIC-derived Evidence: Nonfatal myocardial infarction Comparator Evidence
.... 14.323 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.324 MAGIC-derived Evidence: Nonfatal stroke Comparator Evidence
.... 14.325 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.326 MAGIC-derived Evidence: Serious hyperglycaemia Comparator Evidence
.... 14.327 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.328 MAGIC-derived Evidence: Severe gastrointestinal events Comparator Evidence
.... 14.329 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.330 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.331 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.332 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 14.333 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.334 Mortality at 14 days
.... 14.335 NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022
.... 14.336 NetEffectContribution: All-cause mortality for Example for GIN 2022
.... 14.337 NetEffectContribution: New onset depression for Example for GIN 2022
.... 14.338 NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022
.... 14.339 NetEffectContribution: Remission of diabetes for Example for GIN 2022
.... 14.340 NetEffectContribution: Treatment with opioids for Example for GIN 2022
.... 14.341 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 14.342 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 14.343 NetEffectEstimate: Bariatric Surgery Example for GIN 2022
.... 14.344 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 14.345 NHANES LBDGLUSI: Fasting Glucose (mmol/L) Variable Definition
.... 14.346 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 14.347 NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition
.... 14.348 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 14.349 NHANES SEQN Respondent Sequence Number
.... 14.350 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 14.351 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight) Variable Definition
.... 14.352 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 14.353 Organ support-free days
.... 14.354 Outcome Importance Rating 100 of All-cause mortality
.... 14.355 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 14.356 Outcome Importance Rating 5 of New onset depression
.... 14.357 Outcome Importance Rating 5 of Remission of diabetes
.... 14.358 Outcome Importance Rating 5 of Treatment with opioids
.... 14.359 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 14.360 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.361 OutcomeDefinition: All-cause mortality
.... 14.362 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 14.363 OutcomeDefinition: Body weight
.... 14.364 OutcomeDefinition: Cardiovascular mortality
.... 14.365 OutcomeDefinition: Diabetes in remission
.... 14.366 OutcomeDefinition: Diabetic ketoacidosis
.... 14.367 OutcomeDefinition: End-stage kidney disease
.... 14.368 OutcomeDefinition: Genital infection
.... 14.369 OutcomeDefinition: HbA1c at 12 months
.... 14.370 OutcomeDefinition: HbA1c at 24 months
.... 14.371 OutcomeDefinition: HbA1c at 36 months
.... 14.372 OutcomeDefinition: HbA1c at 6 months
.... 14.373 OutcomeDefinition: HbA1c at 60 months
.... 14.374 OutcomeDefinition: Health-related quality of life
.... 14.375 OutcomeDefinition: Heart failure
.... 14.376 OutcomeDefinition: Mortality at 14 days
.... 14.377 OutcomeDefinition: New onset depression
.... 14.378 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.379 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 14.380 OutcomeDefinition: Nonfatal stroke
.... 14.381 OutcomeDefinition: Serious hyperglycaemia
.... 14.382 OutcomeDefinition: Severe gastrointestinal events
.... 14.383 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.384 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 14.385 OutcomeVariable: HbA1c at 12 months
.... 14.386 OutcomeVariable: HbA1c at 24 months
.... 14.387 OutcomeVariable: HbA1c at 36 months
.... 14.388 OutcomeVariable: HbA1c at 6 months
.... 14.389 OutcomeVariable: HbA1c at 60 months
.... 14.390 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.391 OutcomeVariable: New onset depression
.... 14.392 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 14.393 OutcomeVariable: Remission of diabetes
.... 14.394 OutcomeVariable_Additional_GI_surgical_procedure
.... 14.395 OutcomeVariable_All_cause_mortality
.... 14.396 OutcomeVariable_Treatment_with_opioids
.... 14.397 Participant Flow Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.398 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 14.399 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 14.400 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 14.401 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 14.402 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 14.403 ParticipantFlowMeasure: Exclusion from analysis
.... 14.404 ParticipantFlowMeasure: Inclusion in analysis
.... 14.405 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 14.406 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 14.407 Placebo
.... 14.408 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.409 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.410 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 14.411 Recommendation Justification Code System
.... 14.412 Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.413 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 14.414 Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.415 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 14.416 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 14.417 Remdesivir
.... 14.418 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 14.419 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.420 Risk Of Bias Type Value Set
.... 14.421 Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide
.... 14.422 Search Strategy for NMA_Diabetes
.... 14.423 SearchResults: PubMed search for Wonder Woman
.... 14.424 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 14.425 SearchStrategy: PubMed search for Wonder Woman
.... 14.426 SearchStrategyCharacteristicCode Value Set
.... 14.427 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 14.428 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 14.429 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 14.430 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 14.431 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 14.432 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.433 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 14.434 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 14.435 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 14.436 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 14.437 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.438 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.439 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 14.440 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.441 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.442 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.443 Therapeutic-dose anticoagulation with heparin
.... 14.444 WebPageCitation: A HEvKA Update Summary